All articles tagged with #regulators
A miscommunication during SpaceX's record‑breaking IPO caused Mirae Asset Securities in South Korea to receive zero retail allocations after it mistakenly treated an early investor-demand inquiry as binding orders. The error left Mirae apologizing to clients and facing regulatory inspections, even as the $86 billion offering moved forward with allocations to other underwriters and broad investor demand.
Ryanair updated its family seating policy following a CMA probe: starting June 25, 2026, adults who don’t pay for advance seat reservations will receive a free seat allocation at check-in (often toward the rear), while those who book seats in advance must pay full price for all family members. The airline says the move aligns with European norms and is revenue-neutral, but CEO Michael O’Leary criticizes regulators for pushing what he calls an anti-consumer “industry standard.”
Paramount is close to completing its $111 billion takeover of Warner Bros. Discovery as regulators in more than a dozen countries sign off; the European Commission is expected to approve ahead of an in-depth probe deadline with a condition to exit Paramount’s joint venture with Universal Pictures, while the DOJ has already cleared the deal with no concessions, though final decisions and potential state challenges remain.
Federal regulators are backing the Trump administration’s plan to accelerate electric service and grid interconnections for energy-hungry AI data centers, aiming to meet surging demand and speed infrastructure, while signaling faster permitting—though the move raises questions about grid reliability and environmental reviews.
Hims & Hers Health posted first-quarter revenue of $608 million and a loss of $0.40 per share, missing expectations of $616.8 million and $0.03, which sent the stock down as much as 10% after hours. The company raised its full-year revenue guidance to about $2.8–3.0 billion from a prior range, with Q2 revenue seen around $2.7 billion by analysts. The results come amid regulatory scrutiny after a Wegovy-like rollout was pulled following a Novo Nordisk lawsuit, and ongoing GLP-1 drug partnerships with Novo Nordisk. Analysts maintain a Moderate Buy rating with a $28.02 price target, implying modest downside from current levels.
More than 1,400 actors, directors and filmmakers signed an open letter opposing the $111 billion Paramount-Warner Bros Discovery merger, warning it would reduce competition, limit opportunities for creators, and cost jobs; Paramount Skydance argues the deal would boost output and maintain competitive, independent avenues as regulators weigh approval.
Chinese regulators reportedly told banks to scale back holdings of U.S. Treasuries citing concentration risk and market volatility, with limits on new purchases and directives to reduce exposure; yields rose and the dollar fell on the news. The move was framed as financial-stability guidance rather than geopolitical maneuvering, and regulators did not specify a target. As of Sep 2025, Chinese banks held about $298 billion in USD-denominated bonds, with unclear how much are Treasuries, adding to market chatter about who will keep financing the U.S. debt.
The United States has opened an antitrust review of Netflix's $83 billion deal with Warner Bros., signaling heightened scrutiny of major media–tech mergers.
Opponents of Netflix’s $83 billion bid for Warner Bros. Discovery are expanding their push into Europe, meeting with industry officials and EU regulators to scrutinize the deal, while Paramount and other groups lobby against it. In the U.S., a Delaware judge declined to speed up Paramount’s lawsuit, and Netflix has reiterated it would run Warner Bros.’ theatrical business largely as today, including about a 45-day release window. Market dynamics show shifting odds in Netflix’s favor as the fight unfolds.
Elon Musk's Tesla plans for Robotaxi services have caused confusion among San Francisco regulators, highlighting regulatory challenges in deploying autonomous vehicles at scale.
Tesla's plans to deploy robotaxis in the San Francisco Bay Area have caused confusion and concern among regulators, as the company has not applied for the necessary permits and is using misleading terminology to promote its services, which are currently limited to small-scale, human-driven trips. Despite Musk's optimistic promises and Tesla's high valuation, the company has yet to launch fully autonomous robotaxis and faces regulatory and technical hurdles.
OpenAI is in discussions with California and Delaware regulators to transition from a nonprofit to a for-profit company, a move that could attract more investors but raises questions about its original mission. The company, valued at $157 billion, faces challenges in valuing its intellectual property and complying with California laws on nonprofit asset distribution. Elon Musk has criticized the shift, and OpenAI's nonprofit board chairman assures that the nonprofit will continue to exist in any new structure. The company has faced internal tensions over AI safety and commercialization.
OpenAI is in preliminary discussions with California regulators to transition from a non-profit to a for-profit company, focusing on the valuation of its intellectual property, including the ChatGPT app.
Morgan Stanley's wealth management arm is reportedly under investigation by multiple regulators including the SEC, OCC, and other Treasury Department offices, causing the bank's shares to fall. The probes are focused on the bank's due diligence on prospective clients, monitoring of financial activity, and international clients. This comes after the bank recently resolved an investigation into its block trading practices. Spokespeople for Morgan Stanley and the regulators did not immediately respond to requests for comment.
Microsoft's aggressive recruitment of AI talent from startups and universities is expected to test regulators and venture capitalists as the tech giant aims to bolster its position in the AI space. The move could potentially raise concerns about competition and innovation, prompting scrutiny from regulators and posing challenges for VCs in retaining talent within their portfolio companies.